Ha. Welker et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF MIBEFRADIL IN HYPERTENSIVE PATIENTS WITH VARYING DEGREES OF RENAL-INSUFFICIENCY, Pharmacology, 56(6), 1998, pp. 297-307
Mibefradil, the first member of the tetralol derivatives, a new class
of calcium antagonists, is used for the treatment of hypertension and
angina pectoris. This study was designed to investigate the effect of
varying degrees of chronic renal impairment on mibefradil pharmacokine
tics and pharmacodynamics. Neither pharmacokinetic nor pharmacodynamic
parameters varied as a function of renal status. Additionally, hemodi
alysis removed only a relatively small fraction of drug from the body.
It was concluded that the majority of renal-failure patients will not
require a change in mibefradil dosage relative to patients with norma
l renal function. Following hemodialysis, supplemental mibefradil trea
tment should not be necessary.